Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma-Reference-Cited by-同舟云学术

Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma

Published:2022-12 Issue:12 Volume:24 Page:1245-1258
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Thielen Frederick W.^ORCID,Heine Renaud J.S.D.^ORCID,Berg Sibren van den,Ham Renske M. T. ten,Groot Carin A. Uyl-de

Funder

Ministerie van VWS

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics (clinical),Oncology,Immunology,Immunology and Allergy

Reference87 articles.

1. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance). OJ L vol. 324 (2007).

2. Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption;Eder;Journal of Market Access & Health Policy,2019

3. Innovation and competition in advanced therapy medicinal products;Enrique;EMBO Molecular Medicine,2019

4. The New and Old Europe: East-West Split in Pharmaceutical Spending;Jakovljevic;Front. Pharmacol.,2016

5. Has The Era Of Slow Growth For Prescription Drug Spending Ended?;Aitken;Health Affairs,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Augmenting the landscape of chimeric antigen receptor T-cell therapy;Expert Review of Anticancer Therapy;2024-06-26

2. Effective Gene Therapy for Metachromatic Leukodystrophy Achieved with Minimal Lentiviral Genomic Integrations;2024-03-14

3. Forecasting the potential impact of cell and gene therapies in France: projecting product launches and patients treated;Frontiers in Medicine;2024-02-19

4. Bayesian cell therapy process optimization;Biotechnology and Bioengineering;2024-02-19

5. Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape;Healthcare;2024-02-11